Morgan Stanley Avrobio, Inc. Transaction History

Morgan Stanley

$1.23 Trillion
Q1 2024

A detailed history of Morgan Stanley transactions in Avrobio, Inc. stock. As of the latest transaction made, Morgan Stanley holds 159,709 shares of AVRO stock, worth $236,369. This represents 0.0% of its overall portfolio holdings.

Number of Shares

159,709

Previous 628,259 74.58%

Holding current value

$236,369

Previous $854,000 76.11%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$1.15 - $1.48 $538,832 - $693,454	-468,550 Reduced 74.58%	159,709 $204,000
Q4 2023 Feb 13, 2024	BUY	$1.22 - $1.62 $130,613 - $173,437	107,060 Added 20.54%	628,259 $854,000
Q3 2023 Nov 15, 2023	SELL	$0.98 - $1.62 $517,509 - $855,475	-528,071 Reduced 50.33%	521,199 $802,000
Q2 2023 Aug 14, 2023	BUY	$0.58 - $1.31 $490,926 - $1.11 Million	846,425 Added 417.28%	1,049,270 $996,000
Q1 2023 May 15, 2023	SELL	$0.76 - $1.82 $258,842 - $619,859	-340,582 Reduced 62.67%	202,845 $202,000

Q4 2022 Feb 14, 2023	BUY	$0.64 - $0.91 $20,292 - $28,853	31,707 Added 6.2%	543,427 $385,000
Q3 2022 Nov 14, 2022	SELL	$0.68 - $1.11 $15,881 - $25,924	-23,355 Reduced 4.36%	511,720 $329,000
Q2 2022 Oct 27, 2022	BUY	$0.75 - $1.33 $50,562 - $89,664	67,417 Added 14.42%	535,075 $492,000
Q2 2022 Aug 15, 2022	BUY	$0.75 - $1.33 $50,562 - $89,664	67,417 Added 14.42%	535,075 $492,000
Q1 2022 Oct 27, 2022	SELL	$1.29 - $4.04 $86,967 - $272,364	-67,417 Reduced 12.6%	467,658 $617,000
Q1 2022 May 13, 2022	BUY	$1.29 - $4.04 $218,079 - $682,978	169,054 Added 56.61%	467,658 $617,000
Q4 2021 Feb 14, 2022	SELL	$3.45 - $6.05 $212,230 - $372,171	-61,516 Reduced 17.08%	298,604 $1.15 Million
Q3 2021 Nov 15, 2021	BUY	$5.53 - $9.28 $1.99 Million - $3.34 Million	360,120 New	360,120 $2.01 Million

Others Institutions Holding AVRO

# of Institutions

Shares Held

28.1M

Call Options Held

Put Options Held

100

View Full List

About AVROBIO, Inc.

Ticker AVRO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,773,900
Market Cap $64.8M
Description
AVROBIO, Inc., a clinical-stage gene therapy company, develops ex vivo lentiviral-based gene therapies to treat rare diseases following a single dose worldwide. Its gene therapies employ hematopoietic stem cells that are collected from patients and modified with a lentiviral vector to insert functional copies of the gene that is defective in the...

More about AVRO

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.

Account